Abstract
Abstract The purpose of this randomized controlled trial was to determine if enhanced recovery after surgery (ERAS) would improve outcomes in patients undergoing minimally invasive esophagectomy (MIE) for esophageal cancer. Patients with esophageal cancer undergoing MIE between March 2016 and August 2018 were enrolled. Patients were randomly divided into 2 groups: ERAS+ group that received a guideline-based ERAS protocol, and ERAS- group that received standard care. The primary endpoint was morbidity after MIE. The secondary endpoints were the length of hospital stay and time to ambulation after the surgery. The perioperative results were also collected and compared. A total of 60 patients in the ERAS+ group and 58 patients in the ERAS- group were included. Demographic and clinical features were similar between the groups. Postoperatively, the overall morbidity rate was lower in the ERAS+ group (33.3% vs. 51.7%; p = 0.04), as was the pulmonary complication rate (16.7% vs. 32.8%; p = 0.04). The ERAS+ group began ambulation at a mean of 2.8 days, as compared to 3.3 days for the ERAS- group (P = 0.001). The length of hospital stay was similar between the groups (9 days vs. 9 days; p = 0.70). Implementation of an ERAS protocol for patients undergoing MIE resulted in earlier ambulation and lower complications, without a further change in overall length of hospital stay.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
